Jazz Pharmaceuticals Plc (JAZZ): Michael Patrick Miller , SVP, US Commercial of Jazz Pharmaceuticals Plc sold 100 shares on Jul 15, 2016. The Insider selling transaction was reported by the company on Jul 18, 2016 to the Securities and Exchange Commission. The shares were sold at $142.43 per share for a total value of $14,243.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 13, 2016, Karen L. Smith (Global Head of R&D and CMO) purchased 580 shares at $143.63 per share price.On Jun 16, 2016, Michael Patrick Miller (SVP, US Commercial) sold 100 shares at $149.64 per share price.Also, On May 26, 2016, Seamus Mulligan (director) sold 27,968 shares at $150.13 per share price.On May 17, 2016, Heather Ann Mcsharry (director) sold 697 shares at $145.20 per share price.
Shares of Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) ended Friday, Jul 15, 2016 session in red amid volatile trading. The shares closed down -0.05 points or -0.04% at $142.38 with 3,06,368 shares getting traded. Post opening the session at $142.43, the shares hit an intraday low of $141.76 and an intraday high of $143.96 and the price vacillated in this range throughout the day. The company has a market cap of $8,603 M and the number of outstanding shares has been calculated to be 6,04,21,794 shares. The 52-week high of Jazz Pharmaceuticals plc – Ordinary Shares is $194.73 and the 52-week low is $108.5.
Company has been under the radar of several Street Analysts.Jazz Pharmaceuticals plc – Ordinary Shares is Initiated by Goldman to Buy and the brokerage firm has set the Price Target at $196. The Rating was issued on Jun 6, 2016.Jazz Pharmaceuticals plc – Ordinary Shares is Upgraded by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 193 from a previous price target of $137 .Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on May 11, 2016.Jazz Pharmaceuticals plc – Ordinary Shares is Reiterated by UBS to Buy and the brokerage firm has raised the Price Target to $ 168 from a previous price target of $162 .The Rating was issued on May 11, 2016.Jazz Pharmaceuticals plc – Ordinary Shares is Upgraded by Sun Trust Rbsn Humphrey to Buy. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Apr 25, 2016.